New research suggests that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds far faster than those who end traditional lifestyle programs.
Published data in a prominent health publication shows that while obese individuals frequently drop a large proportion of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month after stopping.
"People purchasing such medications must be informed of the risk of quick weight regain when the medication concludes," warns expert Dr. Susan Jebb.
That rate of regain implies a return to original mass in about a year and a half.
Comparing Approaches
The analysis, which looked at dozens of trials involving thousands of patients, compared the effects of these new drugs with other pills.
Scientists emphasize that people who lose weight through dieting usually experience a slower creep back—around 100 grams monthly—post-intervention.
The Reason for the Rapid Rebound
Experts propose the mode of action of the drugs is key to understanding the heightened weight return.
The injections imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' means appetite is uncontrolled, making overeating far more likely."
A Lifelong Issue?
Health authorities advise the injections for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, due to the likelihood of weight regain, the therapy is often ongoing.
This opinion is echoed by pharmaceutical companies, who state that the results "underscore the persistent character of excess weight," akin to managing diseases like hypertension.
User Testimonies
Users who have stopped the jabs describe a intense return of cravings.
"I experienced something activating and you're instantly starving," said one woman.
This difficulty is compounded if users have not established lasting lifestyle or habit modifications during treatment.
Growing Interest
Recent estimates show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is higher among women than men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while these medications are effective tools for shedding pounds, they are not a permanent fix and long-term success hinges on combined behavioural support.
